Engineering the Extraordinary - Investor Presentation
Q3 & H2FY23 guidance (as provided on November 22, 2022)
Expectations reflect unique combination of timebound headwinds while investing in quality and pipeline
сл
5
Q3 FY23
guidance¹
Outlook does not assume any material recovery in markets
currently experiencing recovery challenges
Organic revenue growth
2.5% to 3.0% $510M headwind
FX: approximately $460M to
Non-GAAP diluted EPS
$1.25-$1.27 FX: approximately $0.05
headwind
Investor Meetings | November 2022
H2 FY23
Revenue &
FY23 EPS
Guidance1
FY22 H2
Revenue base
Organic revenue
growth guidance
Implied revenue
FX1
range
$15,852M
+3.5% to +4.0% -$0.93B to -$1.03B ~$15.4B - $15.6B
FY22 Non-
GAAP EPS base
Implied constant
currency growth
FX1
EPS guidance
$5.55
-1% to -2%
-$0.18
$5.25 $5.30
-
EPS guidance does not include any charges or gains that would be reported as non-GAAP adjustments to earnings during the fiscal year.
1 While FX rates are fluid, assumptions above are based on recent rates near the specific earnings call.
MedtronicView entire presentation